Trends in HRT and anti-osteoporosis medication prescribing in a European population after the WHI study

Osteoporosis International

Volumn 19, Issue 7, 2008, Pages 1047-1054

  Huot, L ^a,b,c   Couris, C M ^a,b,c,d   Tainturier, V ^e   Jaglal, S ^f   Colin, C ^a,b,c   Schott, A M ^a,b,c,d,g  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

^d INSERM   (France)

^e Direction Régionale du Service Médical de l'Assurance Maladie   (France)

^f UNIVERSITY OF TORONTO   (Canada)

^g Hospices Civils de Lyon   (France)

Author keywords

Bisphosphonates; Guidelines; Hormone replacement therapy; Osteoporosis; Raloxifene

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; ETIDRONIC ACID; GESTAGEN; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BILLING AND CLAIMS; DATA BASE; DRUG UTILIZATION; ESTROGEN THERAPY; EUROPE; FEMALE; FRANCE; GENERAL PRACTITIONER; GROUPS BY AGE; GYNECOLOGY; HEALTH INSURANCE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; MONOTHERAPY; OSTEOPOROSIS; PHARMACEUTICAL CARE; POSTMENOPAUSE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOLOGY; TREND STUDY;

AGED; BONE DENSITY CONSERVATION AGENTS; CROSS-SECTIONAL STUDIES; DIPHOSPHONATES; DRUG PRESCRIPTIONS; FEMALE; FRANCE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RALOXIFENE;

EID: 44649111220     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-008-0587-1     Document Type: Article

References (27)

1. Manson JE, Bassuk SS, Harman SM et al (2006) Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause 13:139-147
2. Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. Jama 288:321-333
3. Castelo-Branco C, Palacios S, Calaf J et al (2005) Available medical choices for the management of menopause. Maturitas 52(Suppl 1):S61-S70
4. Cranney A, Guyatt G, Griffith L et al (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570-578
5. Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Jama 282:637-645
6. Barrett-Connor E, Grady D, Sashegyi A et al (2002) Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. Jama 287:847-857
7. Hodsman AB, Bauer DC, Dempster DW et al (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688-703
8. Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419-427
9. Agence Nationale d'Accréditation et d'Evaluation en Santé, Agence Française de Sécurité Sanitaire des Produits de Santé. Audition publique: Les traitements hormonaux substitutifs (THS) de la ménopause, Rapport d'orientation 11 mai 2004. Available at: http://agmed.sante.gouv.fr/pdf/10/roths.pdf. Accessibility verified August 16, 2007.
10. Gayet-Ageron A, Amamra N, Ringa V et al (2005) Estimated numbers of postmenopausal women treated by hormone therapy in France. Maturitas 52:296-305
11. Morabia A, Costanza MC (2006) Recent reversal of trends in hormone therapy use in a European population. Menopause 13:111-115
12. Institut National de la Statistique et des Etudes Economiques. Estimation de population par région, sexe et grande classe d'âge - Années 1990 à 2004. Available at: http://www.insee.fr/fr/ffc/ docs_ffc/elp_reg_dep.htm. Accessibility verified August 16, 2007
13. Agence Française de Sécurité Sanitaire des Produits de Santé. Traitement médicamenteux de l'ostéoporose post-ménopausique. Actualisation 2006. Available at: http://agmed.sante. gouv.fr/pdf/5/rbp/ostemarg.pdf. Accessibility verified August 16,2007
14. Austin PC, Mamdani MM, Tu K et al (2003) Prescriptions for estrogen replacement therapy in Ontario before and after publication of the Women's Health Initiative Study. Jama 289:3241-3242
15. Haas JS, Kaplan CP, Gerstenberger EP et al (2004) Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 140:184-188
16. Hersh AL, Stefanick ML, Stafford RS (2004) National use of postmenopausal hormone therapy: annual trends and response to recent evidence. Jama 291:47-53
17. Majumdar SR, Almasi EA, Stafford RS (2004) Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. Jama 292:1983-1988
18. Usher C, Teeling M, Bennett K et al (2006) Effect of clinical trial publicity on HRT prescribing in Ireland. Eur J Clin Pharmacol 62:307-310
19. Caisse Nationale d'Assurance Maladie des Travailleurs Salariés (2004) Ostéoporose: étude des prescriptions des biphosphonates et du raloxifène. Available at: http://www.ameli.fr/fileadmin/user_upload/ documents/OSTEOPOROSE.pdf. Accessibility verified August 16, 2007
20. Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541
21. McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333-340
22. Rizzoli R (2006) Long-term outcome of weekly bisphosphonates. Clin Orthop Relat Res 443:61-65
23. Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010-2018
24. Code de la Sécurité Sociale (2004) Article L.162-4. Journal Officiel du 19 décembre 2003
25. Perez-Edo L, Ciria Recasens M, Castelo-Branco C et al (2004) Management of osteoporosis in general practice: a cross-sectional survey of primary care practitioners in Spain. Osteoporos Int 15:252-257
26. Jaglal SB, Weller I, Mamdani M et al (2005) Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong? J Bone Miner Res 20:898-905
27. Couris CM, Duclos A, Rabilloud M et al (2007) A seventy percent overestimation of the burden of hip fractures in women aged 85 and over. Bone 41:896-900